BioLife Solutions Inc.
TRT holds patents and intellectual property rights to a process of removing and storing stem cells from umbilical cord tissue. Mesenchymal stem cells are the progenitor cells for muscle, bone, and connective tissues. Published uses of mesenchymal cells in cell therapy include treatment of auto-immune and inflammatory diseases, cancer, heart disease, and tissue engineering.
John E. Davies, President of TRT, Professor of Biomaterials and Biomedical Engineering at the University of Toronto, and inventor of the HUCPVC (Human Umbilical Cord PeriVascular Cell) technology, commented: "As with all cell-based therapies, post-preservation yield and viability are critically important and directly related to clinical efficacy and the overall success of product development, commercial production, and the cost of delivering the therapy to the patient. Our use of CryoStor was driven by a need for a high performance, serum free, fully defined, GMP compliant preservation media. CryoStor uses only USP or highest-available grade components. All of these safety and quality factors led to our decision to adopt this new enabling technology."
BioLife Chairman and CEO Mike Rice remarked: "We are very pleased to be able to provide a key component that substantially improves the preservation and utility of umbilical cord tissue derived stem cells. As a result, TRT and its partners around the world can now offer parents not only a new source of stem cells but also a more viable means of preserving and storing stem cells for the potential treatment of numerous diseases. TRT's adoption of CryoStor represents further validation of the benefits of CryoStor and proof of growing customer acceptance of all our proprietary preservation media products by the cell therapy market."
About Tissue Regeneration Therapeutics
TRT is a private, Canadian life sciences company that exclusively licensed HUCPVC technology from the University of Toronto. TRT's business model involves licensing HUCPVC technology to national Cord Blood Banks seeking to offer new families a mesenchymal stem cell product in addition to their existing cord blood storage. In June 2006, TRT exclusively licensed rights for the Canadian market to CReATe Cord Blood Bank in Toronto, who market HUCPVCs as Peristem™. In June 2007, TRT licensed exclusive USA rights for HUCPVC technology for familial banking to Stem Cell Authority, Akron OH. TRT's preclinical and clinical development program is designed to define patient benefits for auto-immune and inflammatory diseases. For more information please visit http://www.verypowerfulbiology.com/.
About BioLife Solutions
BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor™ platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce or prevent preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit http://www.biolifesolutions.com/.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Media Relations: Investor Relations: Len Hall Matt Clawson Allen & Caron Inc. Allen & Caron Inc. (949) 474-4300 (949) 474-4300len@allencaron.com matt@allencaron.com
First Call Analyst:
FCMN Contact:
SOURCE: BioLife Solutions Inc.
CONTACT: media, Len Hall,
Clawson,
BioLife Solutions
We believe the promise of cell and gene therapies starts with the integrity of a single cell
Advancing the future of cell and gene therapy
The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to protect that promise.
We understand the technical demands of bioprocessing in this field, and our advanced biopreservation expertise, cell culture optimization products, innovative storage systems, and closed-system manufacturing solutions are designed to enhance process efficiency, maintain cellular viability, and ensure reproducibility at every stage. Whether scaling up from R&D, navigating clinical trials or optimizing cryopreservation protocols for commercial production, we provide the tools and experience to streamline your workflow and safeguard your therapies.
Streamline workflows and safeguard therapies
GMP-COMPATIBLE
Precision
biopreservation
for
maximum
viability
GMP-COMPATIBLE
Our biopreservation media and storage solutions are engineered to maintain cell integrity and functionality. With GMP-compatible, validated formulations, we help you reduce variability and improve post-thaw recovery, ensuring robust and reproducible outcomes.
CELL VIABILITY
Best
practices
in
cell
processing
CELL VIABILITY
With deep industry experience, regulatory support, and a commitment to innovation, BioLife Solutions is dedicated to supporting bioprocess engineers in overcoming complex manufacturing challenges. Whether optimizing cryopreservation protocols or ensuring the seamless transition from lab to clinic, we are dedicated to your success.
QUALITY & COMPLIANCE
Scalable
manufacturing
and
process
optimization
QUALITY & COMPLIANCE
Enhance efficiency and consistency in your cell processing workflow with our closed-system tools for fluid management and cell processing that are automation ready. Reduce manual handling errors, improve throughput, and achieve higher standards of quality and compliance as you scale towards commercialization.
REGULATORY SUPPORT
Your
partner
in
bioprocess
optimization
REGULATORY SUPPORT
BioLife Solutions delivers specialized tools and expertise to help bioprocess engineers streamline and strengthen biopreservation processes across the cell therapy workflow. From selecting the right biopreservation media to minimizing cell loss during freezing, storage, and transports, our solutions are designed to improve consistency, reduce risk, and support a successful transition from development to clinical application.
Work with experts who understand your biopreservation challenges
Connect with
our
experts
Explore
our
solutions
Collaborative and comprehensive CDMO support
At BioLife Solutions, we partner with leading contract development and manufacturing organizations (CDMOs) to enhance their biopreservation and cell processing capabilities. By providing advanced tools, regulatory support, and process optimization strategies, we empower CDMOs to better serve therapy developers, ensuring quality, consistency, and scalability in cell therapy manufacturing.
Regulatory
readiness
Navigating the complex regulatory landscape of cell and gene therapy requires a proactive approach. BioLife Solutions offers experienced regulatory support to help prepare your biopreservation and cell processing methods to meet global standards. From IND and BLA submissions to compliance with GMP, FDA, and EMA guidelines, our solutions help streamline approval pathways.
STORE
CellSeal®
CryoCase
Alleviate CGT container challenges like fracture risk, bag burping or high rates of particulates
Data-driven
decision making
Stay ahead with our comprehensive Evidence Library, a curated collection of scientific publications, white papers, and case studies demonstrating the efficacy of BioLife Solutions’ technologies. Access peer-reviewed research, real-world application data, and expert insights to support your bioprocessing and regulatory strategies.
